A meta-analysis of cerebrospinal fluid visinin-like protein-1 in alzheimer's disease patients relative to healthy controls and mild cognitive impairment patients

被引:7
作者
Hu, Xiaohui [1 ]
Yang, Yan [2 ]
Gong, Daokai [1 ]
机构
[1] Yangtze Univ, Jingzhou Clin Med Coll, Jingzhou Cent Hosp, Dept Neurol, Jingzhou, Hubei Province, Peoples R China
[2] Hubei Coll Chinese Med, Wuhan, Hubei Province, Peoples R China
关键词
NEURONAL INJURY; BIOMARKER; YKL-40; CSF; DIAGNOSIS; SECRETASE; DEMENTIA; VILIP-1; RATES;
D O I
10.17712/nsj.2017.2.20160557
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: To compare cerebrospinal fluid visinin-like protein-1 (CSF VLP-1) in alzheimer's disease (AD) with that in healthy controls and mild cognitive impairment (MCI) patients and find out possible sources of heterogeneity. Method: "Visinin-like protein-1" and "alzheimer's disease" were employed to search "PubMed", "Springer" and "Medline" databases until July 2016 and standard mean difference (Std. MD) was calculated. Besides, subgroup analysis and meta-regression were performed to explore the possible heterogeneity sources. Results: Seven studies involved 1151 participants were pooled. The CSF VLP-1 in AD patients was higher than that in healthy controls and MCI patients (pooled Std. MD=0.81, 95% CI: [ 0.47, 1.16], p<0.00001). As shown by subgroup analysis, population variations were one of heterogeneity sources. Meta-regression revealed that Hedges's g of CSF VLP-1 was correlated with Std. MD of t-tau (r=0.560, p=0.006) and A beta 42 (r=-0.386, p=0.013). Conclusion: The CSF VLP-1 in AD patients is higher than that in healthy controls and MCI patients. The changes of VLP-1 in AD patients relative to healthy controls and MCI patients is less pronounced than that of core biomarkers, such as A beta 42, t-tau and p-tau. Population variations, increasing t-tau and decreasing A beta 42 in AD patients relative to healthy controls and MCI patients were the main sources of heterogeneity.
引用
收藏
页码:94 / 101
页数:8
相关论文
共 24 条
  • [1] Relationship Between β-Secretase, Inflammation and Core Cerebrospinal Fluid Biomarkers for Alzheimer's Disease
    Alcolea, Daniel
    Carmona-Iragui, Maria
    Suarez-Calvet, Marc
    Belen Sanchez-Saudinos, M.
    Sala, Isabel
    Anton-Aguirre, Sofia
    Blesa, Rafael
    Clarimon, Jordi
    Fortea, Juan
    Lleo, Alberto
    [J]. JOURNAL OF ALZHEIMERS DISEASE, 2014, 42 (01) : 157 - 167
  • [2] Cell number changes in Alzheimer's disease relate to dementia, not to plaques and tangles
    Andrade-Moraes, Carlos Humberto
    Oliveira-Pinto, Ana V.
    Castro-Fonseca, Emily
    da Silva, Camila G.
    Guimaraes, Daniel M.
    Szczupak, Diego
    Parente-Bruno, Danielle R.
    Carvalho, Ludmila R. B.
    Polichiso, Livia
    Gomes, Bruna V.
    Oliveira, Lays M.
    Rodriguez, Roberta D.
    Leite, Renata E. P.
    Ferretti-Rebustini, Renata E. L.
    Jacob-Filho, Wilson
    Pasqualucci, Carlos A.
    Grinberg, Lea T.
    Lent, Roberto
    [J]. BRAIN, 2013, 136 : 3738 - 3752
  • [3] YKL-40: A Novel Prognostic Fluid Biomarker for Preclinical Alzheimer's Disease
    Craig-Schapiro, Rebecca
    Perrin, Richard J.
    Roe, Catherine M.
    Xiong, Chengjie
    Carter, Deborah
    Cairns, Nigel J.
    Mintun, Mark A.
    Peskind, Elaine R.
    Li, Ge
    Galasko, Douglas R.
    Clark, Christopher M.
    Quinn, Joseph F.
    D'Angelo, Gina
    Malone, James P.
    Townsend, R. Reid
    Morris, John C.
    Fagan, Anne M.
    Holtzman, David M.
    [J]. BIOLOGICAL PSYCHIATRY, 2010, 68 (10) : 903 - 912
  • [4] Calcium/calmodulin-dependent kinase II and Alzheimer's disease
    Ghosh, Anshua
    Giese, Karl Peter
    [J]. MOLECULAR BRAIN, 2015, 8
  • [5] Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer's disease
    Hellwig, Konstantin
    Kvartsberg, Hlin
    Portelius, Erik
    Andreasson, Ulf
    Oberstein, Timo Jan
    Lewczuk, Piotr
    Blennow, Kaj
    Kornhuber, Johannes
    Maler, Juan Manuel
    Zetterberg, Henrik
    Spitzer, Philipp
    [J]. ALZHEIMERS RESEARCH & THERAPY, 2015, 7
  • [6] Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer's disease
    Janelidze, Shorena
    Hertze, Joakim
    Zetterberg, Henrik
    Waldo, Maria Landqvist
    Santillo, Alexander
    Blennow, Kaj
    Hansson, Oskar
    [J]. ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2016, 3 (01): : 12 - 20
  • [7] Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer's disease in a memory clinic cohort
    Kester, Maartje I.
    Teunissen, Charlotte E.
    Sutphen, Courtney
    Herries, Elizabeth M.
    Ladenson, Jack H.
    Xiong, Chengjie
    Scheltens, Philip
    van der Flier, Wiesje M.
    Morris, John C.
    Holtzman, David M.
    Fagan, Anne M.
    [J]. ALZHEIMERS RESEARCH & THERAPY, 2015, 7
  • [8] The brain injury biomarker VLP-1 is increased in the cerebrospinal fluid of Alzheimer disease patients
    Lee, Jin-Moo
    Blennow, Kaj
    Andreasen, Niels
    Laterza, Omar
    Modur, Vijay
    Olander, Jitka
    Gao, Feng
    Ohlendorf, Matt
    Ladenson, Jack H.
    [J]. CLINICAL CHEMISTRY, 2008, 54 (10) : 1617 - 1623
  • [9] Predictive Value of Cerebrospinal Fluid Visinin-Like Protein-1 Levels for Alzheimer's Disease Early Detection and Differential Diagnosis in Patients with Mild Cognitive Impairment
    Leko, Mirjana Babic
    Borovecki, Fran
    Dejanovic, Nenad
    Hof, Patrick R.
    Simic, Goran
    [J]. JOURNAL OF ALZHEIMERS DISEASE, 2016, 50 (03) : 765 - 778
  • [10] Structural Analysis of Mg2+ and Ca2+ Binding, Myristoylation, and Dimerization of the Neuronal Calcium Sensor and Visinin-like Protein 1 (VILIP-1)
    Li, Congmin
    Pan, Wensheng
    Braunewell, Karl H.
    Ames, James B.
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2011, 286 (08) : 6354 - 6366